Pete Stavropoulos
Stock Analyst at Cantor Fitzgerald
(2.06)
# 2,982
Out of 5,072 analysts
52
Total ratings
30.61%
Success rate
0.24%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Pete Stavropoulos
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NVAX Novavax | Initiates: Overweight | $18 | $6.69 | +169.06% | 1 | Oct 24, 2025 | |
| ALEC Alector | Downgrades: Neutral | n/a | $1.28 | - | 6 | Oct 22, 2025 | |
| JSPR Jasper Therapeutics | Downgrades: Neutral | n/a | $1.75 | - | 5 | Jul 7, 2025 | |
| DRUG Bright Minds Biosciences | Assumes: Overweight | n/a | $65.53 | - | 1 | Jul 2, 2025 | |
| VERA Vera Therapeutics | Maintains: Overweight | $107 → $100 | $29.43 | +239.79% | 8 | May 7, 2025 | |
| VYGR Voyager Therapeutics | Reiterates: Overweight | n/a | $3.97 | - | 2 | Mar 12, 2025 | |
| ARCT Arcturus Therapeutics Holdings | Reiterates: Overweight | n/a | $6.80 | - | 6 | Mar 7, 2025 | |
| PLRX Pliant Therapeutics | Reinstates: Neutral | n/a | $1.56 | - | 5 | Mar 4, 2025 | |
| KALV KalVista Pharmaceuticals | Reiterates: Overweight | n/a | $13.28 | - | 1 | Dec 9, 2024 | |
| ANNX Annexon | Reiterates: Overweight | n/a | $4.44 | - | 9 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $10.25 | - | 1 | Oct 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | n/a | $44.09 | - | 1 | Jun 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $5 | $9.53 | -47.53% | 3 | Sep 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $13 | $1.94 | +570.10% | 2 | Jul 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $8 | $18.30 | -56.28% | 1 | Mar 20, 2023 |
Novavax
Oct 24, 2025
Initiates: Overweight
Price Target: $18
Current: $6.69
Upside: +169.06%
Alector
Oct 22, 2025
Downgrades: Neutral
Price Target: n/a
Current: $1.28
Upside: -
Jasper Therapeutics
Jul 7, 2025
Downgrades: Neutral
Price Target: n/a
Current: $1.75
Upside: -
Bright Minds Biosciences
Jul 2, 2025
Assumes: Overweight
Price Target: n/a
Current: $65.53
Upside: -
Vera Therapeutics
May 7, 2025
Maintains: Overweight
Price Target: $107 → $100
Current: $29.43
Upside: +239.79%
Voyager Therapeutics
Mar 12, 2025
Reiterates: Overweight
Price Target: n/a
Current: $3.97
Upside: -
Arcturus Therapeutics Holdings
Mar 7, 2025
Reiterates: Overweight
Price Target: n/a
Current: $6.80
Upside: -
Pliant Therapeutics
Mar 4, 2025
Reinstates: Neutral
Price Target: n/a
Current: $1.56
Upside: -
KalVista Pharmaceuticals
Dec 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $13.28
Upside: -
Annexon
Nov 15, 2024
Reiterates: Overweight
Price Target: n/a
Current: $4.44
Upside: -
Oct 18, 2024
Reiterates: Overweight
Price Target: n/a
Current: $10.25
Upside: -
Jun 27, 2024
Initiates: Overweight
Price Target: n/a
Current: $44.09
Upside: -
Sep 19, 2023
Reiterates: Overweight
Price Target: $5
Current: $9.53
Upside: -47.53%
Jul 17, 2023
Reiterates: Overweight
Price Target: $13
Current: $1.94
Upside: +570.10%
Mar 20, 2023
Reiterates: Overweight
Price Target: $8
Current: $18.30
Upside: -56.28%